Cas9 Stable Cell Line - 266-6

The Cas9-stable 266-6 cell line is a genetically engineered derivative of the murine pancreatic acinar cell line 266-6; the parental cell line was originally isolated from the pancreatic tissue of adult mice. This modified cell line stably expresses CRISPR-associated protein 9 (Cas9), thereby endowing it with precise and highly efficient genomic editing capabilities. As a parental line derived from pancreatic exocrine cells, 266-6 exhibits a typical epithelial morphology and retains key functional characteristics of pancreatic acinar cells, including the capacity for enzyme synthesis and polarized secretion. The stable integration of the Cas9 gene within these cells ensures the long-term and consistent expression of the nuclease, thereby eliminating the need for repetitive transfection procedures. The Cas9-stable 266-6 cell line is characterized by robust growth in DMEM-based basal media, high transfection efficiency, and compatibility with various sgRNA delivery methods; it provides a highly physiologically relevant research platform for in-depth, gene-level investigations into pancreatic biology and the pathogenesis of associated diseases.

In the study of pancreatic pathophysiology, this cell line facilitates targeted gene knockout, thereby enabling the construction of models for exocrine dysfunction disorders such as pancreatitis. This allows researchers to delve deeply into the functions of key genes—such as PRSS1 (trypsinogen) or SPINK1—and the roles they play in enzyme activation and inflammatory cascades. Researchers can also utilize this cell line to conduct high-throughput functional genomics screens to identify novel regulators of acinar cell dedifferentiation—a critical step in the initiation phase of pancreatic ductal adenocarcinoma (PDAC). In the field of regenerative medicine, this cell line supports the precise editing of developmental genes (e.g., PDX1, SOX9), thereby enabling the artificial modulation of "acinar-to-ductal metaplasia"—a process of cellular fate conversion—and providing a crucial theoretical basis for elucidating the mechanisms of tissue repair and regeneration. In the realm of drug discovery and screening, this cell line accelerates the validation of drug targets through the generation of "isogenic pairs." This enables researchers to precisely evaluate the efficacy of candidate drug compounds—targeting specific gene mutation sites—within cellular models that simulate pancreatic insufficiency or diseases associated with cystic fibrosis.